Trials / Completed
CompletedNCT02772419
Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
A Phase 2, Double-Blind, Placebo-Controlled Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy and safety of SC administrations of Benralizumab or Placebo in the subjects with Eosinophilic Chronic Rhinosinusitis in a multicenter, randomized, double-blind, placebo-controlled study. The pharmacokinetics and immunogenicity will be assessed secondarily.
Detailed description
Screening Period (maximum 4 weeks) , Randomized Treatment Period (24 weeks)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | benralizumab | SC administration |
| DRUG | benralizumab | SC administration |
| DRUG | Placebo | SC administration |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-03-27
- Completion
- 2017-03-27
- First posted
- 2016-05-13
- Last updated
- 2018-04-23
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02772419. Inclusion in this directory is not an endorsement.